Evidence map›Paper›PMID 28540466›Full record

ArticleInternational journal of clinical pharmacy2017

Drug utilization evaluation of albumin in a teaching hospital of Mashhad, Iran: an interventional pre-post design study.

Farzaneh Zolfagharian, Saba Ghazanfari, Sepideh Elyasi, Paria Iraji, Mohammad Reza Saberi, Nasser Vahdati-Mashhadian, Amir Hooshang Mohammadpour

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Clinical and economic impacts of clinical pharmacists' interventions in Iran: a systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019
    Pooled it
  2. Observational
  3. Albumin: a comprehensive review and practical guideline for clinical use.European journal of clinical pharmacology · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Farzaneh ZolfagharianDepartment of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Saba GhazanfariDUE Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Sepideh ElyasiDepartment of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Paria IrajiDepartment of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Reza SaberiMedical Chemistry Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Nasser Vahdati-MashhadianMedical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Hooshang MohammadpourDepartment of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. MohamadpoorAH@mums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Albumin is a protein colloidal solution with limited availability and high cost. It should be used in such approved indications as paracentesis, extensive burn, spontaneous bacterial peritonitis, and nephrotic syndrome. Objectives The aim of this study was to evaluate and compare the appropriateness of albumin usage before and after an evidence-based guideline. Setting Four wards of Imam Reza Hospital, Mashhad, Iran. Method An interventional pre-post design study was performed on 2 groups of patients; in gGroup 1 as a preparation phase group in 6 months from February 2015 to July 2015 and Group 2 as an interventional group from September 2015 to February 2016. A guideline for proper indications of albumin, designed and finalized based on the physicians' comments, was implemented in Group 2. Main outcome measure The pattern of albumin consumption. Results Fifty patients were evaluated in each group. The implementation of the guideline resulted in reduction of improper albumin use from 62 to 57.5%, which was not statistically significant; however., it reduced inappropriate dose and duration of albumin therapy (55.5-16.7%), the number of consumed albumin vial, and the average cost for each patient (317.78 ± 3.15-149.81 ± 1.91 USD) significantly, as well. Conclusion This study illustrated that in this hospital in most cases, albumin was used inappropriately and at an alarming rate. This improved after the introduction of an evidence-based guideline. Moreover, guideline implementation resulted in significant cost reduction.

Indexed as

AdolescentAdultAgedAlbuminsBurnsDrug Utilization ReviewEvidence-Based MedicineFemaleHospitals, TeachingHumansIranMaleMiddle AgedPractice Guidelines as TopicShockYoung AdultAlbuminsAlbuminCost reductionDrug use evaluation (DUE)Inappropriate useInterventionIranTeaching hospital

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.